NCT07616297Recruiting
Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients
REctal Organ Preservation With a BOost Approach Using CBCT-based Online Adaptive radioTherapy
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
The goal of this prospective study is to evaluate if a higher radiation dose to the tumor can increase the organ preservation rate in non-locally advanced rectal cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 13 Mar 2026
- Start date
- 27 Jan 2026
- Primary completion date
- 1 Aug 2029
- Lead sponsor
- Claudia Schuurhuizen
- Diseases
- Colorectal cancer
- NCT number
- NCT07616297
What you commit to
- Study type: Interventional
- Planned participants: 25
- From 27 Jan 2026 to the primary completion date, 1 Aug 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiotherapy in the pelvic area
- Other malignancies, except for adequately treated basal cell carcinoma (BCC), at time of inclusion or within 3 years prior to inclusion
- Contra-indications for (chemo)radiotherapy or surgery
- Prior local excision of the primary tumor
Other
- Presence of lateral lymph nodes, cN2 status, extramural vascular invasion (EMVI) or mesorectal fascia involvement as seen on MRI
- Mucinous defined tumor on MRI
- DPD (dihydropyrimidine dehydrogenase) deficiency
- Unable to understand the requirements of the study and to give written informed consent, as determined by the treating physician
Who the study is looking for
- Age ≥18 years
- Eastern cooperative oncology group (ECOG) performance status ≤2
- Histologically confirmed rectal adenocarcinoma
- Non-locally advanced rectal cancer, defined as (magnetic resonance imaging (MRI)-based) T1-3, N0/N1 (≤3 positive mesorectal lymph nodes), MX/M0
- Indication for curative treatment with organ preservation
- Discussed in the multidisciplinary tumor board (MTB)
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus MC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.